Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487351 | 0.86 | MAPK1 (0.58) | MAPK1TSHRMAPTPKMLMNA | |
| SCHEMBL12693585 | 0.83 | TSHR (0.55) | MAPK1TSHRMAPTPKMLMNA | |
| SCHEMBL27958762 | 0.82 | TSHR (0.58) | MAPK1TSHRMAPTPKMLMNA | |
| SCHEMBL10853042 | 0.81 | PDE7A (0.51) | MAPK1TSHRMAPTPKMLMNA | |
| SCHEMBL437440 | 0.79 | TSHR (0.58) | MAPK1TSHRMAPTPKMLMNA | |
| SCHEMBL28244904 | 0.79 | TSHR (0.58) | MAPK1TSHRMAPTPKMLMNA | |
| SCHEMBL2016758 | 0.78 | MAPT (0.63) | MAPK1TSHRMAPTPKMLMNA | |
| SCHEMBL2976885 | 0.78 | MAPT (0.58) | MAPK1TSHRMAPTPKMLMNA | |
| SCHEMBL16752918 | 0.78 | MAPK1 (0.53) | MAPK1TSHRMAPTPKMLMNA | |
| Hydrochloric Acid SCHEMBL28169484 | 0.77 | TSHR (0.56) | MAPK1TSHRMAPTPKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198309-B2 | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl)hetaryl arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100331302-A1 | N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331302-A1 | N-(2-(HETARYL)ARYL) ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CCR9, CCR2, CCR10 | MAPK1 3160/4885TSHR 1974/4885MAPT 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.